Investors who have incurred losses can register their claims with the platform at: http://wq.finance.sina.com.cn/. Follow @Sina Securities on WeChat, search for Sina Securities and Funds on WeChat, or visit Sina Finance client and homepage to access the service.

南新制药 (688189) focuses its product development on innovative drug research, building a structured pipeline of ongoing and existing products. The company has established a strong presence across several therapeutic categories, including anti-influenza drugs, oncology treatments, diabetic nephropathy drugs, cardiovascular and cerebrovascular medications, and anti-infective agents.

The company is classified under the Shenwan industry system as follows: Primary Industry - Medical Biology; Secondary Industry - Chemical Pharmaceuticals; Tertiary Industry - Chemical Preparations.

On August 14, 2026, the company disclosed an Administrative Penalty Decision, revealing the following violations: In 2023, 南新制药's subsidiary, Guangzhou Nanxin, failed to adjust revenue and profits after customer returns. This resulted in the 2023 annual report overstating revenue by 44.3588 million yuan, or 5.96% of the period's total revenue, and inflating total profit by 9.0877 million yuan, which represented 119.46% of the reported profit figure.

Additionally, in 2023, Guangzhou Nanxin entered into an Accounts Receivable Agreement with a client. After the agreed cash discounts took effect, the company did not reduce revenue and profits accordingly. This led to an overstatement of revenue by 20.3240 million yuan in the 2023 annual report, or 2.73% of the period's revenue, and an inflated profit of 2.8645 million yuan, equating to 37.65% of the reported profit.

These combined actions led to a total overstatement of 64.6828 million yuan in 2023 annual revenue, or 8.69% of the total, and an inflated profit of 11.9522 million yuan, which was 157.11% of the reported profit for the period. The stock's performance following the investigation is noted.

The eligible claim window is provisionally defined as investors who purchased shares between March 26, 2024, and September 30, 2025, and who either sold or continued to hold them on or after October 1, 2025. This includes both individual and institutional investors. (Access the claim entry point for 南新制药). The final parameters for the claim period will be determined by a legally binding court judgment.